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Abstract
Despite esophageal adenocarcinoma (EAC) being the most
widespread among gastrointestinal cancers, with an 11-fold
increase in the risk of cancer for patients with Barrett esophagus
(BE), its prognosis is still poor. There is a critical need to better
perceive the biology of cancer progression and identiﬁcation of
speciﬁc targets that are the hallmark of BE's progression. This
review explores the established animal models of BE, including
genetic, surgical and nonsurgical approaches, potential chemo-
prevention targets, and the reasoning behind their applications
to prevent Barrett-related EAC. The key methodological features
in the design feasibility of relevant studies are also discussed.
Cancer Res; 78(14); 3747–54. 2018 AACR.
Introduction
Barrett esophagus: Deﬁnition and epidemiology
The esophagus is a muscular tube, which joins the proximally
located pharynx to the distally located stomach. The esophagus is
a very well assembled system with many efﬁcient and complex
protective tools against reﬂux injury. This includes the antireﬂux
barriers (restricting the gastric chyme from accessing the esoph-
agus), the luminal clearancemechanisms (ensuring a short period
of contact between the reﬂuxate and the esophageal epithelium),
and the tissue resistance (which minimizes the damage to the
esophageal epithelium; ref. 1). If the gastroesophageal reﬂux is
persistent, it causes chronic mucosal injury and inﬂammation.
Many tumors of the digestive system arise under such conditions,
including esophageal adenocarcinoma [EAC; from Barrett esoph-
agus (BE)], gastric cancer (from Helicobacter pylori–associated
gastritis), hepatocellular cancer (from viral hepatitis), and colon
cancer (from inﬂammatory bowel disease).
BE is a preneoplastic lesion in which the normal, stratiﬁed
esophageal squamous epithelium is substituted with intestinal-
type columnar epithelium. Such a conversion from esophageal to
intestinal-type cells is known as intestinal metaplasia (IM). IM
originates at the junction of the distal esophagus and the gastric
cardia, that is, the gastroesophageal junction (GEJ). BE is consid-
ered to be the precursor to EAC and progresses frommetaplasia to
low-grade dysplasia (LGD) and high-grade dysplasia (HGD),
which can end with invasive adenocarcinoma. Figure 1 depicts
anatomy and physiology of the human and murine upper
gastrointestinal tract.
The epidemiology of esophageal cancers in the United States
has undergone a major change since 1975, when 75% of all
cases were squamous cell cancer (SCC) affecting primarily the
middle portion of the esophagus. Today, the rate of SCC has
fallen slightly while that of EAC near the GEJ has risen
dramatically (2). In 1975, EAC affected 4 people per million,
in 2001, this rate escalated to 23 people per million, making it
the fastest-growing cancer in the United States (3). The
dramatic increase in the disease incidence is not due to an
overdiagnosis; in fact, EAC mortality has increased in parallel
with incidence (2). EAC is distinguished by six prominent
characteristics: increasing occurrence, male prevalence, lack
of preventive measures, opportunities for early detection,
challenging surgical therapy and care, and poor prognosis (4, 5).
BE and EAC
The possibility of EAC in patients with BE is low, with 0.12%
affected annually in unselected populations and 0.26% in
patients with HGD (6). However, this corresponds to an 11-fold
increase in the risk of cancer for patients with BE as opposed to
those without (7). Thus, 1 of 200 patients with BE will acquire
esophageal cancer every year (8). BE is observed in 5% to 15% of
patients who are searching for medical care for chronic heartburn
(9). However, due to the prevalent accessibility of acid-suppres-
sant medications, numerous patients with reﬂux symptoms
choose to not be subjected to an expensive endoscopy unless
their symptomsare persistent or refractory tomedical therapy. The
pathogenesis of BE is likely a two-step process. The ﬁrst step
involves the transformation of normal esophageal squamous
mucosa to a simple columnar epithelium called cardiac mucosa.
This occurs in response to chronic injury produced by chronic
episodes of gastric juice reﬂuxing onto the squamous mucosa.
The change from squamous to cardiac mucosa likely occurs
relatively quickly, within a few years, while the second step, the
development of goblet cells indicative of IM, proceeds slowly,
probably over 5 to 10 years (10). Because BE is a precursor of
EAC, screening is an attractive strategy to decrease cancer deaths
from EAC. Unfortunately, recent guidelines from the American
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Gastroenterological Association (AGA) do not recommend
endoscopic screening for patients with reﬂux symptoms due to
its cost (8). Moreover, proper diagnosis is complex and varies in
different countries. For instance, in the United Kingdom, the
British Society of Gastroenterology does not consider IM a
required parameter (11). The complexity of proper diagnosis
arises from the differences in the distinction between LGD and
HGDwithin the BE crypts (12). The comprehensive list of known
and available biomarkers of BE is included here (13).
The purpose of this review is to present a comprehensive list of
available animal models used to study BE as well as discuss the
current status with the literature overview of the major chemo-
prevention options for BE.
Risk factors
In order to prevent any disorder, it is of primary importance to
understand its risk factors, and in the case of esophageal cancer,
every type has different risk factors. Someof the greatest origins for
EACs arise from a history of gastroesophageal reﬂux disease
(GERD; refs. 14, 15): BE, regurgitation, obesity (16, 17), dietary
factors such as low in vitamin D intake (18) and antioxidant
content (19), lifestyle, genetic predisposition (20, 21), and smok-
ing (22–24). Moreover, bulimia nervosa, the eating disorder,
could be a possible risk factor in the pathogenesis of EAC (25).
The decliningHelicobacter pylori prevalence inWestern countries is
associated with higher rates of BE and EAC (26) as well as cardia
cancer, which share features of both, esophageal and gastric
cancers (27).
Diagnosis
Clinical challenges in proper identiﬁcation of patients with
BE include ﬁnding cost-effective and improving the diagnostic
potential of endoscopic screening. Thus far, it has neither been
shown that screening for BE improves mortality from adenocar-
cinoma, nor is the process cost effective (28). According to AGA,
an endoscopic screening is recommended for patientswith several
risk factors related to EAC, such as old age, male sex, white race,
chronic GERD, hiatal hernia, elevated bodymass index, and intra-
abdominal distribution of fat; ref. 8). Guidelines for diagnosing
BE include columnar liningmeasurement, speciﬁcally that there is
at least a 1 cm threshold of columnar lining above the GEJ. In
addition, patients with BE require minimum of 8 biopsies. It is
also proposed that endoscopists should utilize the Prague clas-
siﬁcation to describe what is seen in the Barrett segment (29). A
recent study evaluated cost effectiveness of screening patientswith
GERD for BEwith aminimally invasive cell sampling device called
Cytosponge (30). The screening was found to be cost effective.
There is a 5-year survival in 83% to 90% of the cases for EAC, if
the tumor is identiﬁed at an early stage whereas a dismal 10% to
15% 5-year survival exists for those with late-stage cancers (28).
Luckily, the development of carcinogenesis is a prolonged one
that offers abundant occasions for intervention.
Treatment
During an evolution of many years, a gradual shift occurs from
LGD to HGD, intramucosal cancer, and lethal disease. The obli-
gation of the endoscopist is to properly identify each of these
© 2018 American Association for Cancer Research
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Figure 1.
Anatomy and physiology of the human
and murine upper gastrointestinal tract.
The esophagus, lined by stratiﬁed
squamous epithelium, in humans joins
the cardia region of the stomach lined by
columnar epitheliumat theGEJ,whereas
in the mouse, it joins the stomach at the
intersection of the forestomach, lined by
squamous epithelium, and the corpus,
lined by columnar epithelium. The GEJ
shows a transition from the squamous to
columnar epithelium.
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stages and assign appropriate therapy. Endoscopic resection with
either endoscopic mucosal resection (EMR) or endoscopic sub-
mucosal dissection (ESD) is the most accurate method for path-
ologic diagnosis and staging (31). Endoscopic resection such as
EMR or ESD allows the removal of large specimens that include
mucosa and submucosa suitable for predictive staging. Different
studies have shown a clear beneﬁt for shorter segments (up to 4 to
5 cm) or noncircumferential BE treated with stepwise EMR (32).
Despite the fact that BE with dysplasia is many times more
common in the West, only two reports on ESD have been
published compared with many on EMR and ablation. Ablation
technique such as endoscopic radiofrequency ablation (RFA) of
dysplastic BE combined with proton pump inhibitor therapy is
frequently used for blocking the advancement of dysplastic BE to
EAC. Additional ablation modalities include antigen-presenting
cell (APC), photodynamic therapy, cryoablation, and multipolar
electrocoagulation. A 2013 U.S. Multicenter Consortium con-
ducted study on 592 patients with BE treated with RFA from
2003 through 2011 and measured the rate of recurrence,
described as the occurrence of IM or dysplasia after complete
remission of IM (CRIM) in surveillance biopsies (33). It was
found that 56% of patients were in complete remission after
24months and 33%had disease relapse within the next 2 years. A
recent Markov analysis by Hur and colleagues suggests that RFA is
cost effective in preventing the progression of HGD to cancer
compared with surveillance (34). They suggest a role for ablation
in conﬁrmed, stable, andmultifocal LGD. The role for ablation in
nondysplastic BE was unclear.
Chemoprevention and Its Challenges
Chemoprevention is a formof a clinical populationprevention,
proposed at diminishing the probability of disease advancement
in recognized high-risk individuals by the use of pharmaceutical
agents (35). In other words, it is the use of speciﬁc preventive
drugs to stop cancerous cells from forming, growing, or recurring.
Prescribing chemotherapy to a patient is one of the most difﬁcult
conundrums for medical practitioners. While chemotherapy can
be beneﬁcial, it can only be successful in certain settings and once
animal studies have truly been exhausted to validate the efﬁcacy of
the pharmaceutical agents.
The challenges of increasing cancer prevention are numerous
and daunting. The increasing rates of patients with BE indicate
that the attitude toward chemoprevention needs to be re-exam-
ined. While tremendous efforts have been devoted to studying
genetic andmolecular changes in BE and EAC, little has translated
so far into clinical practice. Identiﬁcation of a highly speciﬁc and
sensitive biomarker, which it purports to detect, would aid in the
identiﬁcation of early disease progression. However, the process
of biomarkers evaluation is analogous to the process in thera-
peutic drug studies; it is complex, demanding, and time
consuming. Table 1 summarizes chemopreventive agents current-
ly used for BE, and their effects, limitations, and modes of action.
Animal Models to Study BE and EAC
There are a large number of cell lines to study BE, with themost
commonly used ones derived from epitheliumof patientswith BE
or EAC. They include CP-D, BAR-T-cell lines from Barrett epithe-
lial cells and OE33, OE19, FLO-1, and SKGT4 from the EAC cell
line. The presence of bile salts and their composition can be tested
in such cell lines to mimic the gastroesophageal reﬂuxate of a BE
patient. Various bile salts, acids, different pHs, pulsatile expo-
sures, and incubation times are being optimized for the most
optimal to the clinical conditions in a number of studies (36–39).
However, further discussion of these studies is beyond the scope
of this review.
Establishment of animal models
Themain challenge in studying theprogression fromneoplastic
lesion to EAC in animals is the lack of true preclinical models that
can express the evolutionary dynamics of Barrett cell populations.
Mouse models differ from humans in lacking gastric reﬂux and
gastric juice production, having a forestomach, and possessing
variability in diet composition and microbiome composition.
These differences present technical limitations in the develop-
ment of a robust animal model that can truly mimic the human
condition. Fromcomputationalmodels,whichoffer ahighdegree
of tractability, enable researchers to both, understand data and to
acquire intuitions and hypotheses for neoplastic progression.
From tissue culture models, which involve squamous cell lines,
BE cell lines and EAC cell lines, we can learn about the microen-
vironment of the cells in two-dimensional conditions. However,
neither of these approaches is foolproof and recapitulates the
diseasemodel of interest. For instance, BIC-1, SEG-1, andTE-7 cell
lines have been recently disputed to not truly represent EAC tissue
culture (40). Moreover, while three-dimensional organotypic
cultures of BE might overcome many issues associated with
two-dimensional cell lines, they do not fully represent a true
microenvironment of the gastrointestinal tract. Mice have a his-
tologically comparable esophagus to rats but, dissimilar to rats,
mice can be easily genetically modiﬁed. Thus, mice can offer a
superior model for studying the molecular modiﬁcations leading
to the development of Barrett metaplasia. Using mice, it is
beneﬁcial to evaluate whether metaplasia of the proximal stom-
ach, stimulated by conditional, localized mechanical destruction
of the squamous epithelium (e.g., by gavage), can be abided and
inﬂuence to neoplasia, with or without genetic lesions involved in
BE. Below, we have highlighted some of the mouse models
currently being used for the study of BE.
Rodent models
Genetic mouse models: p63-null mouse model. The transcription
factor p63 is necessary for epidermal lineage commitment, epi-
dermal differentiation, cell adhesion, and basement membrane
formation (41). This factor is part of a family that comprises two
structurally associated proteins, p53 and p73. p63 knockoutmice
have considerable defects in their limb and craniofacial develop-
ment, including a remarkable lack of stratiﬁed epithelia (42, 43).
p63-null embryos have idiopathic metaplastic changes together
in the esophagus and proximal stomach, as two typically squa-
mous tissues in mouse models (44). Although the mouse upper
gut is generally lined by squamous epithelium from themouth to
the middle of stomach, p63-null embryos instead demonstrate a
well-built columnar epithelium (45). Conversion of the stratiﬁed
squamous esophageal epithelium to a columnar, intestinal-like
epithelium, via a metaplasia is a key feature occurring in BE
pathology.
The McKeon group has recently reported that BE originates
from a minor population of nonesophageal cells leftover from
early development (44). Furthermore, they assume that the initial
spread of these cells derives not from genetic alterations but
from competitive interactions between cell lineages, driven by
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opportunity. This mousemodel is used to indicate the progress of
a Barrett-like metaplasia in embryonic mice from precursor cells.
While the developmental model serves as a good tool to address
future questions as to why obscure residual embryonic cells of BE
origin persist postnatally, it cannot serve as a useful tool for
studying chemoprevention.
L2-IL1bmouse model. In humans, high levels of IL1b can promote
chronic inﬂammation and carcinogenesis (46, 47). Carriers of
IL1b polymorphisms (IL1b-511T and IL1b-31C) correlated with
increased systemic levels of the cytokine have an increased risk of
gastric cancer, and targeted overexpression of IL1b in the stomach
of mice causes gastric inﬂammation and cancer (48, 49). Similar
ﬁndings have been reported in BE, where genetic polymorphisms
of IL1RA, the endogenous IL1 receptor antagonist, have been
associated with higher systemic IL1b levels and to a higher risk
of BE among patients with GERD (50). Raised levels of IL1b and
IL8 have also been reported in biopsies of BE compared with
squamous esophageal mucosa (51).
Over time, L2-IL1b mice develop esophageal hyperplasia
and metaplastic BE lesions that resemble human BE in gene
expression proﬁle. The L2-IL1bmouse model provides insights
into the early pathogenesis of BE and proposes a molecular
basis for an emerging distinct concept concerning the cell of
origin of BE and EAC. In a recent study, we used IL1b mice to
show that hypergastrinemia increases proliferation and expan-
sion of Barrett-like esophagus and accelerates a progression
from BE to EAC using CCK2Rþ progenitor cells (52). In
addition to IL1b, metaplasia can be accelerated in this mouse
model by feeding the mice 0.2% deoxycholic acid, an uncon-
jugated bile acid that is a key component of the duodenal
reﬂuxate that promotes BE in GERD (53). While both genetic
mouse models, p63 null and L2-IL1b, support the hypothesis
that BE arises from progenitor cells in the cardia, with the
L2-IL1b mouse model, the mice survive to adulthood and
develop progression to EAC.
p27 knockout model. Because, in human studies, most Barrett-
associated adenocarcinomas are lacking tumor suppressor gene
p27, p27 knockout mice were used to conduct a study where
animals were exposed to a carcinogen,methylbenzylnitrosamine,
following induction of the gastroduodenal–esophageal reﬂux
(54). As expected, the highest incidence of EAC was observed in
p27 knockout mice. This useful mouse model could serve as an
example in cultivating techniques to prevent malignant transfor-
mation of BE; however, due to a small mouse size and associated
postsurgical complications, their utility is limited.
Transitional basal cells at the squamous-columnar junction model.
Whilenomousemodel trulymimics BE in termsof thepresence of
intestinal goblet cells, a mouse model provided evidence that the
distinct basal progenitor cells (p63þKRT5þKRT7þ), in the newly
identiﬁed transitional zone in the epitheliumof theupperGI tract,
are the cells of origin formultilayered epitheliumandBE (55). The
study showed that basal cells (p63þKRT5þ) in the transitional
epithelium served as progenitors for KRT7þ BE-like epithelium in
mice. The (Lgr5þ) cardia mucosa consistently did not contribute
to the transitional epithelium in Lrg5CreER;R26LacZ mice. Using
lineage tracing, it was revealed that the columnar epithelium
lining the p63/ esophagus, forestomach and squamocolumnar
junction is derived from p63 promoter active basal progenitors.
Surgical mouse models. In addition to genetic engineering
approaches, mice serve as a tool in reﬂux-inducing surgeries. A
mouse surgical reﬂux model to evaluate Barrett metaplasia and
esophageal carcinogenesis that summarizes both the histologic
and molecular changes prominent in human Barrett metaplasia
has beendevelopedby inducing acid reﬂuxafter following an end-
to-side esophagojejunostomy (EJ; ref. 56). As early as 13 weeks
after EJ, esophagitis with esophageal erosions and squamous
epithelial thickening with basal cell layer hyperplasia has been
observed. Within 34 weeks, columnar intestinal-type metaplasia
looking like that of human BE was detected in 1 of 6 animals with
erosive esophagitis. The metaplasia occurred with the presence of
goblet cells. By 13months following surgery, just 1 of 13 animals
had esophageal IM. No adenocarcinoma or squamous cell carci-
nomas were detected. Gastroesophageal reﬂux was surgically
induced in wild-type (WT), p53A135V transgenic, and INK4a/
Arfþ/mice but it did not produce EAC (57). On the other hand,
total gastrectomy resulting in jejunoesophageal reﬂux was
performed in WT, p53-knockout (Trp53/), or APC-mutated
(APCMin/þ) mice to show that the loss of Trp53, but not APC,
results in the incidence of cancer and loss of either Trp53 or APC
leads to the development of columnarmetaplasia. Unfortunately,
due to the short life span of p53-knockout mice, application of
such a model is still limited (58).
Ratmodel. In 1962, the ﬁrst attempt to produce esophagitis in rats
was performed using EJ, which yielded a high incidence rate of
pancreatic reﬂux and slightly lower incidence of bile reﬂux (59).
This was achieved by performing a combination of transplanta-
tion of the bile duct to a jejunal loop, gastrectomy, and trans-
plantation of the bile duct to jejunum and diversion of pancreatic
secretions. There were no metaplastic or neoplastic changes;
however, the healing of traumatized squamous epithelium with
glandular replacement has been observed shortly after (60). The
occurrence of glandular islands of heterotopia and ectopia in the
rat stomach after repeated trauma by open gastrostomy was
present.
Rats were also used to model the reﬂux through the pylorus
or through an end-gastrojejunostomy (61). While no cancers
were detected in any of the animals with gastrotomy, gastric
adenocarcinoma developed in 41%. The follow-up study was
devised to conclude whether esophageal cancer could be
provoked by a reﬂux of gastroduodenal contents (62). Though
no neoplasia was perceived in the control rats, the experimental
rats with duodeno-forestomach reﬂux and duodeno-glandular-
forestomach reﬂux developed adenocarcinomas in the lower
esophagus. Rats following the EJ were administered MF-tricyclic
(10 mg/kg/day) and sulindac (30 mg/kg/day), resulting in
lower incidence of EAC in the MF-tricyclic þ sulindac groups
than in the control group and lower degree of inﬂammation in
both groups (P < 0.001) showing that both selective and
nonselective COX-2 inhibitors might have chemopreventive
potential in BE (63). In another study, rats following the EJ
were out on diets containing 1% ursodeoxycholic acid (Urso)
and 0.3% acetylsalicylic acid (asprin). Drug combination
reduced the risk of adenocarcinoma in animals with reﬂux (in
the combination group, 26% of animals developed esophageal
cancer vs. 62% in the control group), decreased proliferation of
EAC cells while no signiﬁcant difference was observed in the
risk of EAC in the groups given Urso alone or asprin alone when
compared with control (64).
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While the surgical rat model has offered valuable understand-
ing into the histologic pathogenesis of Barrett metaplasia, it has
not been used to look into the fundamental molecular mechan-
isms involved in Barrett pathogenesis due to limitations in genetic
engineering.
Large animal models
Because rodents do not possess a natural reﬂux, drugs such as
proton pump inhibitors cannot be tested readily in these models.
Therefore, surgical intervention of EJ provides a truemodel with a
chronic reﬂux esophagitis. Only surgically modiﬁed animals can
serve as a part of the clinical background. While experiments on
the canine model represent one of the best models as it truly
produces reﬂux and leads to an IM, since the 1970s (65) and
1980s (66) the studies have fallen out of use due to numerous
bans at higher education institutions.
Concluding Remarks and Future
Perspectives
The occurrence of EAC is increasing in Western countries. BE is
the only identiﬁed precursor of EAC. While one of the most
common predisposing factors to BE is the presence of gastro-
esophageal acid reﬂux, most patients presenting with EAC report
no history of acid reﬂux. Hence, these asymptomatic patients
would not have undergone endoscopy, with a possibility of BE
remaining undiagnosed during its early stages. Preemptive
approaches for high-grade dysplasia and BE, such as RFA and
photodynamic therapy, have achieved dramatic results; however,
there are reports of recurrences in the long run. Therefore, the
main challenges in theﬁeld remain identifying (i) the origin of BE,
(ii) a single, reliable risk factor for BE development to aid
diagnosis, (iii) uniformity in diagnostic criteria, and (iv) thera-
peutic drug development for BE and EAC. Identiﬁcation of che-
mopreventive agents depends greatly on epidemiologic and path-
ologic data procured from human patients, animal models, and
cell cultures. As enumerated in this article,multiple chemopreven-
tive and therapeutic drugs are being used for BE and EAC;
however, an effective course of action can only be taken after
reliable diagnosis with histologic and molecular markers. With
increasing knowledge and understanding of the pathology and
progression of BE, its therapy is promising in the near future.
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